Mattel Gains Over 2% – What’s Going On?

Mattel shares surge as the company announces plans for a feature-length film based on "Bob the Builder," featuring Anthony Ramos and celebrating Caribbean Latin nations' vibrant textures.

Mattel, Inc. (NASDAQ:MAT) shares are trading higher on Friday.

Yesterday, the company announced plans to develop a feature-length film based on Bob the Builder, the beloved animated children’s series.

The movie will be developed together with ShadowMachine, Nuyorican Productions, and Anthony Ramos, the company said in a press release.

The film will star Grammy-winning and Golden Globe and Emmy-nominated actor and recording artist Anthony Ramos, for the voice of Roberto, “Bob,” travels to the enchanting Island of Puerto Rico for a significant construction job. 

Bob’s journey will celebrate the vibrant and colorful textures of the Caribbean Latin nations and their people, the company said.

Robbie Brenner, President of Mattel Films, said: “We are thrilled to collaborate with our brilliant partners Anthony Ramos, Jennifer Lopez, Elaine Goldsmith-Thomas, Benny Medina, Alex Bulkley, Corey Campodonico, and Felipe Vargas on Bob the Builder, our first animated theatrical film.”

Following the success of Warner Bros’ “Barbie” movie, which grossed over $1.4 billion at the box office, Mattel has unveiled “Bob the Builder” as the latest addition to its slate of film and television projects, Reuters said in a report.

In 2011, Mattel acquired Hit, the owner of rights to “Bob the Builder,” “Thomas & Friends,” and other preschool properties, for $680 million.

Price Action: MAT shares are trading higher by 2.32% to $18.52 on the last check Friday. 

Photo via Company

Total
0
Shares
Related Posts
Read More

Azitra, Inc. Announces Preclinical Data From The Co’s Platform And Pipeline On Friday, May 10, 2024, In Two Oral Sessions Entitled “Engineered Staphylococcus Epidermidis As A Protein Delivery System For Treating Skin Diseases” And “Staphylococcus Epide…

Azitra will present two oral presentations at ASGCT (American Society of Gene and Cell Therapy) Baltimore, MD, May 7-11, 2024 related to ATR-12, Azitra's candidate for Netherton syndromeTopical application of ATR-12 to

AZTR